Albumin and the fatty acids interactions

Y Coleman,

3rd June 2025
Examples of PharmacoNutrition ie some common blood tests impacted by some commonly prescribed medicines

Mechanisms and consequences

Albumin and the fatty acids (FAs) interactions have an important physiological relationship. Albumin is a key carrier for many of the fatty acids, normally binding up to 99% non-esterified fatty acids (NEFAs). NEFAs are free (unbound), typically long chain, fatty acids. The binding affinities of fatty acids are dependent upon carbon chain length.

Types of binding

When binding to albumin, fatty acids alter its structure allosterically. This means fatty acid binding at X site alters what (other substances) can be carried at Y site.

Substances are not able to simultaneously occupy the same binding site on albumin.

Factors that can alter fatty acids binding to albumin include dietary fat (type and quantity), and some prescribed medicines.

The binding on albumin can be co-operative or competitive.

Co-operative binding

Occurs when both compounds are able to interact with albumin simultaneously.

Co-operative binding can also be allosteric. For example, Site I (Sudlow Site 1, subdomain IIA) and Heme site (FA1, subdomain IB) are allosterically coupled. Consequently, Site I compounds may affect the bindings of Heme site compounds with albumin and vice versa.

Co-operative binding can cause changes in binding affinity.

Competitive binding

Compounds cannot be bound simultaneously if they both bind to the same binding site or their binding sites overlap. For example, α-linolenic acid binds to FA7 (subdomain IIA) and warfarin binds to Site 1 (subdomain IIA). FA7 overlaps Site 1 so when both want to bind at the same time the binding is competitive.

When compounds compete for the same binding site, the outcome is determined by their concentrations and affinities. For example, α-linolenic acid has a higher affinity for albumin than warfarin.

Fatty acid binding-induced changes

Fatty acid binding causes changes to albumin’s structure (shape change) and consequently function.

Structural/shape change

Albumin is quite flexible structurally in order to accommodate the various shapes and sizes of its load.

Examples of fatty acids changing albumin’s shape -

   - binding of fatty acids cause Site 1 (subdomain IIA) to extend significantly beyond subdomain IIA;

   - binding of long chain fatty acids causes domains I + III to rotate relative to domain II;

   - FA1 (subdomain IB) partially overlaps with haem site (subdomain IB). Consequently, haem and some fatty acids can change the shape of subdomain IB;

   - pocket accommodation of fatty acids in FA2 (subdomains IA + IIA interface) requires domain I rotation relative to domain II;

   - binding of fatty acids can alter the volume of the FA7 (subdomain IIA) binding site;

   - FA9 (subdomains IA-IB-IIA + IIB-IIIA-IIIB interface) is formed by a fatty acid inducing structural change.

The consequences of changes in the albumin structure impacts various –

 - nutrients - by altering their availability;

 - drugs – by ultimately affecting their availability and/or effectiveness.

Changing function

Structural change typically alters albumin’s carrying capacity and therefore function. Examples include -

  • fatty acids binding to FA2 (subdomains IA+IIA interface) alters access to MBS-A (Metal Binding Site-A, subdomains I + II interface). This compromises the binding of MBS-A to calcium, cobalt, copper, magnesium, manganese, and zinc;
  • binding of fatty acids can alter Site 1’s volume and polarity;
  • some drugs can bind with fatty acids sites. Binding of drugs to fatty acid sites increases drug half-life and plasma solubility, but reduces their free active concentration.

Fatty acids sites summary

Nine fatty acids and their binding sites are currently identified.

Identification of the 9 binding sites locations for the 9 fatty acids on albumin in MedNut Mail article Albumin and fatty acids

FA1

Subdomain IB - aka the haem binding pocket, haem site, haem pocket FA1

Binds Haem, bilirubin, biliverdin, hemin

FA2

Between subdomains IA and IIA

Palmitate, stearate

FA3

Subdomain IIIA + IIB

α-tocopherol

Fatty acids with carbon groups -

  - ≤ 12-14 - linearly

   - ≥ 12-14 folded

FA4

Subdomain IIIA

α-tocopherol

Longer chain fatty acids - folded

FA5

Subdomain IIIB

Single fatty acids molecules

 Palmitate

FA6

Between subdomains IIA + IIB

Medium and long chain fatty acids

FA7

Subdomain IIA

α-linolenic acid

FA8

Between subdomains IA-IB-IIA and subdomains IIB-IIIA-IIIB.

Short chain fatty acids

FA9

Between subdomains IA-IB-IIA and subdomains IIB-IIIA-IIIB.

Short-chain fatty acids eg capric acid

Fatty acids and their binding sites by subdomain

Subdomain

Fatty acids

IA


IB

FA1

IIA

FA7

IIB


IIIA

FA3, FA4

IIIB

FA5

Domain

Fatty acids

IA-IIA interface

FA2

IIA-IIB interface

FA6

IA-IB-IIA and IIB-IIIA-IIIB interface

FA8, FA9

Clinical Concerns

We are accustomed to direct (linear) cause and effect interactions between pharmaceuticals and nutrition. For example, proton pump inhibitors alter gastric pH and consequently impair absorption of minerals such as magnesium, iron, calcium, etc.

The combination of structural flexibility, overlapping binding sites and allostery adds extra complexity to interactions between pharmaceuticals and nutrition. Allostery is comparable to thinking around corners!

Further, the structural flexibility, overlapping binding sites, allostery trifecta is an area where the clinical need-to-know is outpacing the research.

Clinical Questions

When you a review a person prescribed one or more drugs that utilize albumin as a carrier -

  • would you question whether their higher serum fatty acids are altering albumin’s capacity to carry drugs and key nutrients?

Conclusions

Albumin and the fatty acids interactions affect which substances, including nutrients, can be carried by albumin at any given time.

Please read this as it is important …

The information in this article is provided to support Health Professionals. It is not an exhaustive protocol and Health Professionals are advised that adequate professional supervision is accessed to ensure that Duty of Care obligations with respect to safe administration of medicines is met for each consumer.

MedNut Mail is a free weeklyish email that consists of 2 components, being:

  • an editorial - based on some aspect of PharmacoNutrition, and 
  • a monthly case study - difficult, simple, all real-life (and not identifiable).
Image of our MedNut Mail icon for our articles on drug-nutrient, drug-food, and pharmaconutrition interactions

Want to make sure you do not miss any articles?

Then subscribe now and have it delivered to your inbox!

Malcare WordPress Security